Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Thymoma 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphatic Metastasis 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1

Interventions

Topotecan 10Etoposide 7Specimen Handling 6berzosertib 5Cisplatin 5Biopsy 5sargramostim 4Platinum 4Magnetic Resonance Spectroscopy 4Irinotecan 4Carboplatin 4trioctyl phosphine oxide 3X-Rays 3Paclitaxel 3Nivolumab 31,2-diaminocyclohexaneplatinum II citrate 3veliparib 2romidepsin 2olaparib 2cabozantinib 2aldesleukin 2Tomography, X-Ray Computed 2Temozolomide 2Sunitinib 2PM 01183 2Electrocardiography 2Depsipeptides 2Decitabine 2Cyclophosphamide 2Budesonide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Small Cell Lung Carcinoma × avelumab × Clear all
NCT06228066 2026-06-05

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
45 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡